Articles
The severity and impact of nausea and vomiting (NV) on patients undergoing chemotherapy and radiotherapy is greater than estimated by oncology physicians and nurses, according to research presented by Cheryl Vidall at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer. Read More ›
The addition of nintedanib to docetaxel therapy did not increase the frequency of adverse events associated with antiangiogenic treatment in non-small-cell lung cancer (NSCLC) patients, according to research presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting. Read More ›
The Annual Meeting of the American Society of Clinical Oncology (ASCO) is the largest and most important oncology specialty meeting in the United States, and arguably the world. More than 30,000 oncology professionals gathered in Chicago, IL, to hear about ground-breaking research, state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Below is a selection of presentations from oral abstracts, posters, and the ASCO education sessions that will be of interest to oncology nurses and advanced practitioners. Read More ›
Ixazomib (Ninlaro) has been approved for use in combination with lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma who have received ≥1 prior therapy. The drug is the first orally-administered proteasome inhibitor Read More ›
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Read More ›
The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A Read More ›
Today, the US Food and Drug Administration (FDA) granted accelerated approval for an oral medication to treat patients with advanced non—small-cell lung cancer (NSCLC). Read More ›
What is the best chemotherapy regimen to use for patients with locally advanced nonsquamous non–small-cell lung cancer (NSCLC)? The phase 3 PROCLAIM trial attempted to answer this question, but the study failed to determine the best regimen for this patient population. Read More ›
The US Food and Drug Administration (FDA) today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients aged ≥12 years. Read More ›
The US Food and Drug Administration (FDA) today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma. Read More ›